BSD Medical Hyperthermia Systems Featured at European Society for Hyperthermic Oncology Annual Conference

  BSD Medical Hyperthermia Systems Featured at European Society for   Hyperthermic Oncology Annual Conference  Business Wire  SALT LAKE CITY -- July 9, 2014  BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced BSD hyperthermia systems were featured in multiple presentations at the European Society for Hyperthermic Oncology (ESHO) Annual Conference. There were many presentations during the conference regarding innovative uses of thermal therapy in the treatment of patients with a variety of cancers. The results of two innovative clinical studies using BSD's hyperthermia systems were presented during the conference.  Dall’Oglio et al., presented data from a study of 144 patients with high risk prostate cancer who were treated using the BSD-2000 Hyperthermia System (BSD-2000) at the University Hospital in Verona, Italy. The presentation was titled "Regional hyperthermia added to hormonal therapy and radiotherapy in T2b -T4 prostate cancer - long-term follow up results." The patients received hyperthermia combined with hormonal therapy and external beam radiotherapy. After a median follow-up of 75.7 months, overall survival was 87% and disease-free survival was 49%.  Puric et al., Aarau, Switzerland, reported results from a retrospective study of the safety and efficacy of hyperthermia, delivered using the BSD-500 Hyperthermia System, combined with radiation in the management of patients with recurrent breast cancer who had received previous radiation. The study, "Hyperthermia and re-irradiation for postirradiated locoregionally recurrent breast cancer: a single institutional experience," involved 24 previously irradiated patients. The researchers reported a complete response rate of 66.7% (16/24) and an overall objective response rate (complete plus partial response) of 91.7% (22 of 24 patients). The follow-up ranged from 1 to 38 months with a median follow-up of 10 months. The researchers concluded that, "Local thermoradiotherapy is an effective and safe modality to treat loco-regional recurrences in previously irradiated breast cancers. It produces sustainable long term effective palliation with minimal morbidity."  About the BSD-2000 Hyperthermia System  The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.  About the BSD-500 Hyperthermia System  The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in conjunction with radiation therapy to treat certain tumors.  About BSD Medical Corporation  BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.  This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.  Contact:  Financial Profiles Tricia Ross, 310-622-8226 tross@finprofiles.com  
Press spacebar to pause and continue. Press esc to stop.